Vural 2010.
| Methods | RCT Open 2005‐2006 |
|
| Participants | Number: 63 patients (99 episodes) Age: med 5 range (2‐14) |
|
| Interventions | piperacillin‐tazobactam 80+10mg/kgX4 versus imipenem‐cilastatin 15mg/mgX4 |
|
| Outcomes | All‐cause and infection‐related mortality (during the neutropenic episode) Clinical failure Drug modifications Adverse events |
|
| Notes | Turkey | |
| Risk of bias | ||
| Bias | Authors' judgement | Support for judgement |
| Adequate sequence generation? | Unclear risk | No description |
| Allocation concealment? | Unclear risk | No description |
| Blinding? All outcomes | High risk | Blinding not used |
| Incomplete outcome data addressed? All‐cause mortality | Low risk | |
| Incomplete outcome data addressed? Treatment failure | Low risk | |
| Free of other bias? | High risk | Unit of randomization = episodes; patients to episodes ratio 0.64 |